Innovative Health Care Portfolio, Series 22
Ticker Symbol: FFVRMX

40 Holdings (As of Day of Deposit)
Ticker Name Initial
Weight
Price*
Biotechnology (37.50%)
ABBV AbbVie Inc. 2.50% $199.35
ALNY Alnylam Pharmaceuticals, Inc. 2.48% 256.21
AMGN Amgen Inc. 2.43% 328.93
BIIB Biogen Inc. 2.51% 200.64
BMRN BioMarin Pharmaceutical Inc. 2.51% 84.85
EXEL Exelixis, Inc. 2.50% 26.31
GILD Gilead Sciences, Inc. 2.50% 81.44
HALO Halozyme Therapeutics, Inc. 2.50% 59.26
INCY Incyte Corporation 2.52% 63.13
MRNA Moderna, Inc. 2.48% 79.28
NBIX Neurocrine Biosciences, Inc. 2.51% 119.10
REGN Regeneron Pharmaceuticals, Inc. 2.59% 1136.35
SRPT Sarepta Therapeutics, Inc. 2.53% 126.94
UTHR United Therapeutics Corporation 2.53% 342.46
VRTX Vertex Pharmaceuticals Incorporated 2.41% 470.78
Health Care Equipment (27.43%)
BSX Boston Scientific Corporation 2.51% 83.06
EW Edwards Lifesciences Corporation 2.48% 67.14
GMED Globus Medical, Inc. 2.49% 69.38
HOLX Hologic, Inc. 2.52% 81.96
PODD Insulet Corporation 2.45% 226.50
ISRG Intuitive Surgical, Inc. 2.48% 484.24
PHG Koninklijke Philips N.V. 2.50% 29.72
MASI Masimo Corporation 2.49% 114.99
MDT Medtronic Plc 2.49% 90.99
STE Steris Plc 2.53% 247.17
SYK Stryker Corporation 2.49% 365.05
Health Care Technology (5.03%):
EVH Evolent Health, Inc. 2.50% 30.30
VEEV Veeva Systems Inc. 2.53% 221.89
Life Sciences Tools & Services (10.00%):
ILMN Illumina, Inc. 2.47% 124.13
IQV IQVIA Holdings Inc. 2.54% 235.20
RGEN Repligen Corporation 2.50% 146.70
TMO Thermo Fisher Scientific Inc. 2.49% 624.21
Managed Health Care (2.51%)
HQY HealthEquity, Inc. 2.51% 74.69
Pharmaceuticals (17.53%)
AZN AstraZeneca Plc 2.49% 81.16
LLY Eli Lilly and Company 2.56% 901.25
JNJ Johnson & Johnson 2.48% 167.38
LGND Ligand Pharmaceuticals Inc. 2.50% 102.23
MRK Merck & Co., Inc. 2.49% 115.33
NVO Novo Nordisk A/S 2.51% 129.78
ZTS Zoetis Inc. 2.50% 191.36

* As of the close of business on 9/10/24.
Market values are for reference only and are not indicative of your individual cost basis.

Not FDIC Insured • Not Bank Guaranteed • May Lose Value

Portfolio Summary
Initial Date of Deposit 9/11/2024
Initial Public Offering Price $10.00 per Unit
Portfolio Ending Date 12/11/2025
Cash CUSIP 30337N100
Reinvestment CUSIP 30337N118
Fee Account Cash CUSIP 30337N126
Fee Account Reinvestment CUSIP 30337N134

Fee Table (based on a $10 public offering price per unit)
  Standard Fee/Wrap
Deferred Sales Charge 1.35%
Creation & Development Fee (C&D Fee) 0.50% 0.50%
Maximum Sales Charge 1.85% 0.50%
     
Estimated Organization Costs 0.510% 0.510%
Estimated Annual Trust Operating Expenses 0.215% 0.215%

The deferred sales charge will be deducted in three monthly installments commencing 12/20/24. When the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the price exceeds $10.00 per unit, you will pay an initial sales charge. The C&D fee is a charge of $0.050 per unit collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the C&D fee will be less than 0.50%; if the price you pay is less than $10.00 per unit, the C&D fee will exceed 0.50%. Estimated organization costs will be deducted from the assets of the trust at the end of the initial offering period. Estimated organization costs and trust operating expenses are assessed on a fixed dollar amount per unit basis which, as a percentage of average net assets, will vary over time. Actual expenses may be more or less than the estimates. Please see “Fee Table” in the trust prospectus for additional information.

You should consider the portfolio's investment objectives, risks, and charges and expenses carefully before investing. Contact your financial professional or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus, which contains this and other information about the portfolio. Read it carefully before you invest.

Risk Considerations
An investment in this unmanaged unit investment trust should be made with an understanding of the risks involved with owning common stocks, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market.

You should be aware that the portfolio is concentrated in stocks in the health care sector which involves additional risks, including limited diversification. The companies engaged in the health care sector are subject to fierce competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends. In addition, health crises, such as a pandemic outbreak, can severely impact the health care industry in particular.

Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.

An investment in a portfolio containing small-cap and mid-cap companies is subject to additional risks, as the share prices of small-cap companies and certain mid-cap companies are often more volatile than those of larger companies due to several factors, including limited trading volumes, products, financial resources, management inexperience and less publicly available information.

Large capitalization companies may grow at a slower rate than the overall market.

As the use of Internet technology has become more prevalent in the course of business, the trust has become more susceptible to potential operational risks through breaches in cybersecurity.

Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain investments as well as performance.

The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.

The value of the securities held by the trust may be subject to steep declines or increased volatility due to changes in performance or perception of the issuers.

This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.

 

CUSIP identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by FactSet Research Systems Inc. and are not for use or dissemination in a manner that would serve as a substitute for any CUSIP service. The CUSIP Database, ©2024 CUSIP Global Services. "CUSIP" is a registered trademark of the American Bankers Association.